Re‑thinking Trial Monitoring: The Case for Randomisation Oversight

Risk‑based monitoring requires sponsors to focus on data critical to patient safety and trial integrity.

This article explores why randomisation is receiving increased regulatory attention and how it fits into modern monitoring strategies.